A new antibiotic to flight multi-resistant bacteria, or superbugs, will be available in New Zealand tomorrow.

It will be used as a last-line response when all other antibiotics fail to treat an infection.

PHARMAC will fund the drug which will cost around 200 thousand dollars a year, for about 20 people.

It will be used on patients with complicated skin and soft-tissue infections and some types of pneumonia.

PHARMAC deputy medical director Dilky Rasiah [dil-key RA-sigh-ya] says antibiotics resistance is a world wide issue, and New Zealand is not exempt.